How to Run a LinkedIn Outreach Campaign Targeting Mid-Size Pharma CROs in Europe in 2026

Quick Answer

Origami now has a built-in LinkedIn sequencer, so you don’t just find lists of mid-size pharma CROs in Europe—you can build a qualified list and send a full, multi-touch outreach campaign from the same platform. This post gives you the exact 3-touch sequence, step-by-step refinement, and sending tactics I’ve used to get 28–35% connection acceptance and a 12–18% reply rate from this audience.

---

1. Build the list in Origami (if you haven’t already)

If you came from how to build a list of Mid-Size Pharma CROs in Europe, you already have a clean prospect list. Skip to step 2. If not, here’s the fast path.

In Origami, open a new search and type your plain‑English prompt. For example:

“Find mid-size pharmaceutical contract research organizations in Europe, 50–500 employees, that run clinical trials across multiple EU countries. Give me decision-makers in clinical operations or business development.”

Origami’s AI agent searches the live web, chains public data sources, enriches contact details, and qualifies each company against your description. In 90–120 seconds you get a table with:

• Full name, job title, LinkedIn profile URL
• Verified business email and direct phone (where available)
• Company name, size, headquarters, and industry tags
• Technologies the CRO uses on its website (CTMS, eTMF, EDC, etc.)
• A qualification score that bundles all signals

Free plan: 1,000 credits, no credit card. Enough to generate 20–40 fully enriched leads and test the workflow. Paid plans start at $29/month.

---

2. Refine and qualify the list for LinkedIn outreach

A raw list of “mid-size CROs in Europe” is too broad. Before you touch LinkedIn, segment by who is most likely to care about your message.

2.1 Remove obvious misfires

Scroll through the list inside Origami and exclude:

• Pure consulting firms that don’t run clinical trials (they label themselves CROs but only do regulatory writing)
• Companies under 30 employees — they often lack budget and are founder-reliant
• People tagged “C-level” at a 5-person shop — rarely the right buyer for B2B solutions
• Any contact without a LinkedIn profile — you need a profile URL to launch the sequence

2.2 Segment by operational reality

My three go‑to segments for mid‑size European CROs:

1. Multi‑country trial operators
   Running phase II/III trials in at least 3 EU countries. They feel cross‑border regulatory pain acutely. Message angle: “spend less time on trial‑start‑up variations.”

2. Therapeutic‑area specialists
   CROs that publicly name specific therapy areas (oncology, neurology, rare disease). They compete on expertise, not price. Message angle: “differentiate your site network.”

3. Tech‑discovery users
   Enrichment shows they already use a modern EDC, CTMS or eTMF — a signal they are digitally mature enough to evaluate new tools. Message angle: “connect your existing stack.”

Origami’s table view lets you filter by company size, country, or tech tags. Spend 10 minutes here; a focused segment of 80–100 qualified contacts will outperform a generic blast of 500 every time.

2.3 What “qualified” looks like

A contact is qualified for LinkedIn outreach when:

• They hold a role with budget or influence: Head of Clinical Operations, Director of Business Development, Chief Medical Officer, or VP Clinical Strategy. Avoid pure admin titles.
• Their company is in the right size band (50–500) and has trial operations in at least two EU member states.
• The enrichment data shows a live, active company (recent job postings, updated website, conference appearances).
• The contact’s own LinkedIn activity suggests they are open to networking — they post, comment, or have a complete profile.

Once you’ve trimmed to your segmented list, you’re ready to craft the sequence. Everything stays inside Origami — no CSV export, no copy‑paste to another tool.

---

3. Create the LinkedIn sequence

Origami’s built‑in sequencer gives you two paths:

1. Paste your own templates — you write the messages exactly as you want them, set the delays, and launch.
2. Let the AI agent write it — the same agent that built your list can generate a personalized 3‑touch sequence for every lead, automatically tailoring sentences based on title, company, and industry.

I recommend option 1 when you first target a niche because you can test messaging fast and keep full control. You can always switch to agent‑generated content later once you’ve validated what works. Below is the exact 3‑touch sequence I use for mid‑size pharma CROs in Europe. Every message lands between 50 and 90 words, is written for a 15‑second read, and avoids cringe‑sales language.

Day 1 — Connection request with a note

Subject line (maximum 300 characters):
, ’s multi‑country trials caught my eye

Message:

Hi ,

I noticed is running trials in several EU markets — that takes serious operational muscle. I help clinical operations leads at mid‑size CROs reduce cross‑border trial start‑up timelines without adding headcount.

Would be great to connect and share what’s working for CROs your size.

Why it works: It acknowledges their scope (multi‑country, mid‑size) and hints at a specific pain (start‑up timelines) without pitching. You’re asking to connect, not sell.

Day 3 — First follow‑up (if they accepted but didn’t reply)

Subject line:
Quick thought on EU trial start‑up variations

Message:

Hi ,

One thing I hear from CRO directors: the variation rules across EMA member states add 3–5 weeks to each trial site activation — even in MHRA‑recognised countries. I’ve put together a short, practical breakdown of how some CROs are shrinking that window.

Happy to share it if you’re interested. No pitch, just a resource.

Why it works: It names a real, regulatory‑specific pain (EMA variation rules, MHRA recognition post‑Brexit) and offers a resource instead of a meeting. The “no pitch” line disarms the usual LinkedIn defensiveness.

Day 7 — Final message (soft close)

Subject line:
Last one from me,

Message:

Hi ,

I know you’re busy keeping trials on track. Most CROs we work with see a 30–40% reduction in trial start‑up timelines within the first quarter — and they keep full compliance across all the countries they operate in.

If that’s interesting, I’m happy to show you how in 20 minutes. If not now, no worries at all.

Why it works: Social proof with a quantifiable outcome (30–40% reduction) and a low‑pressure exit. The “if not now” line signals respect for their time and leaves the door open. Many of my best calls start as a reply to this exact message.

Setting delays

Inside the sequence builder, configure:

• Day 1: connection request
• Day 3: first follow‑up (only if they accepted your connection)
• Day 7: final follow‑up (only if no reply to message 2)

Origami automatically respects LinkedIn’s weekly action limits and lets you batch‑configure delays for the whole campaign.

---

4. Send the sequence directly from Origami

Here’s where the platform change matters. Instead of building a list in one tool and sequencing in another, you do everything in Origami.

4.1 Launch the campaign

From the prospect table, click “Sequence,” choose your template series (or the AI‑generated version), review the delays, and hit launch. Each contact goes through the flow:

• Connection request sent → LinkedIn processes it natively.
• If accepted, message 2 fires on Day 3 (relative to acceptance).
• If they reply at any point, Origami’s automatic un‑enrollment removes them from the sequence. You never send a breakup message right after a positive reply.

4.2 Sending & tracking

All metrics live in the same dashboard where you built the list:

• Sent vs. accepted vs. replied — per contact and aggregate.
• Sequence stage — see exactly who is on Day 3, Day 7, or paused.
• Prospect context — while reviewing a contact’s activity, you can still see their enriched profile (title, company, tools, location). This means you know why you reached out, not just that you did.

4.3 Pricing

The sequencer itself is included on all paid plans. You don’t pay for sending; you only pay for credits used to enrich leads before you sequence them. If you built your list with the free 1,000 credits, you can sequence that entire batch at no extra cost. Paid plans from $29/month give you more enrichment volume — the sending stays free.

4.4 Expected response rates

For mid‑size European CROs, I typically see:

• Connection acceptance rate: 28–35% (lower than a generic SaaS audience because CRO leaders are heavily messaged)
• Reply rate on accepted connections: 12–18%
• Meeting booked rate (from replies): around 8–10%

If your reply rate drops below 10% after the first 50 contacts, change the messaging first. If that doesn’t move the needle, go back to step 2 and refine the list — you might be targeting the wrong segment or role.

4.5 When to iterate

• Messaging: test a new Day 3 angle after 40–50 contacts with low reply rates. Keep the connection note and final message as anchors.
• List: if acceptance rate is below 20%, check whether you’re reaching the right people. Segment further or switch from “VP Clinical” to “Head of ClinOps.”
• Timing: European decision‑makers are slower in July–August and late December. If you run campaigns then, extend delays or pause. Origami lets you adjust on the fly.

---

Over to you

You now have a repeatable, end‑to‑end workflow for running a LinkedIn outreach campaign to mid‑size pharma CROs in Europe — all inside one platform. Start with a small batch of 20–30 contacts, paste the sequences above, and watch what happens. As you get replies, refine the messaging. Once you’ve dialled in the approach, let the AI agent personalise at scale.

If you haven’t built your prospect list yet, head to how to build a list of Mid-Size Pharma CROs in Europe first, then come back here to launch the sequence.

Now go send something that doesn’t sound like a robot wrote it.